Peninsula biotech coughs up 40 percent of its value on failed clinical trial

A Peninsula drug developer's only drug failed a mid-stage clinical trial in chronic cough — its second thumbs down in the clinic since going public eight months ago — sending the company's stock down 40 percent in trading Monday.